Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 800 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 800 shares of Pharvaris stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $36.19, for a total transaction of $28,952.00. Following the transaction, the director directly owned 115,167 shares of the company’s stock, valued at $4,167,893.73. The trade was a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, September 17th, Johannes Gerardus Chri Schikan sold 200,000 shares of Pharvaris stock. The shares were sold at an average price of $35.00, for a total value of $7,000,000.00.
• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88.
• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $241,424.40.

Pharvaris Trading Down 0.2%

Shares of PHVS stock opened at $32.99 on Friday. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25. The stock has a fifty day simple moving average of $35.35 and a two-hundred day simple moving average of $31.98. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.82 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Research analysts predict that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Analyst sentiment remains supportive: Wells Fargo, Cantor Fitzgerald, Leerink Partners and Citizens JMP maintain positive ratings, with several raising price targets to $65–$79. The consensus rating is “Moderate Buy,” with an average target of $59.87. Pharvaris analyst ratings and insider trading report
• Positive Sentiment: Institutional ownership trends were favorable, including a new approximately $160.6 million position by venBio Partners, a 12.9% increase by Wellington Management and a 144.6% increase by Seven Fleet Capital. These purchases may signal confidence in Pharvaris’ oral hereditary angioedema treatment platform.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no days-to-cover and little evidence of meaningful short-selling pressure. However, the figure may reflect a reporting or data anomaly given the company’s trading volume.
• Negative Sentiment: Several executives sold shares. CFO David Nassif sold 6,000 shares for approximately $218,820, while Director Johannes Gerardus Chri Schikan sold 800 shares in a separate filing. Additional reports cited sales of 200,000 shares by Schikan, 52,500 by Elisabeth Bjork and 100,000 by Peng Lu. The cluster of insider selling could weigh on sentiment, although executives retained sizable holdings. Pharvaris insider selling report
• Negative Sentiment: Pharvaris remains loss-making and recently reported a quarterly loss of $0.81 per share, wider than the $0.75 analyst estimate. Analysts expect a full-year loss of approximately $3.12 per share, leaving the stock dependent on clinical and regulatory progress for further upside.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PHVS. Leerink Partners increased their price objective on Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Wells Fargo & Company upped their target price on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Pharvaris in a research report on Monday, September 14th. Finally, Citizens Jmp lifted their price objective on shares of Pharvaris from $75.00 to $79.00 and gave the company a “market outperform” rating in a research note on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and a consensus price target of $59.87.

Institutional Trading of Pharvaris

A number of hedge funds have recently modified their holdings of PHVS. Engineers Gate Manager LP purchased a new position in Pharvaris during the second quarter valued at approximately $1,143,000. Amundi boosted its position in Pharvaris by 61.4% in the 2nd quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after purchasing an additional 18,992 shares in the last quarter. Moore Capital Management LP acquired a new stake in shares of Pharvaris during the 2nd quarter worth approximately $1,522,000. Alyeska Investment Group L.P. grew its stake in shares of Pharvaris by 225.5% during the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after purchasing an additional 281,829 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares in the last quarter.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.